The Global Health Body Raises Alert Over Acute Lack of Obesity Jabs
Fewer than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy have access to them, caution the global health agency as it releases its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just access to GLP-1 medication.
Per projections, over two billion could be living with obesity by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to widespread availability to the treatments that can aid individuals in losing substantial body mass, notes the body.
Skinny Jab Scarcity
Even under the present most favorable outlook, the supply of these medications could only cover around 100 million people – less than 10% of the global need, per the health organization.
The guideline encourages countries and companies to expand availability, through approaches like licensing agreements.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is set to lapse in several nations in 2026.
How Weight-Loss Drugs Operate
These medications replicate a biological compound to delay gastric emptying, reduce hunger and increase satiety so people consume fewer calories.
Individuals usually start to lose weight in the initial weeks of commencing the regular doses.
Studies suggests people may see weight return after a year of halting the treatment, as their normal appetite return.
To be overweight or obese elevates your likelihood for contracting health problems, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects people in every country and was associated with over three and a half million deaths worldwide in 2024, as per the health agency.
